Namodenoson | MedDataX

Drug Profile

Namodenoson is an orally bioavailable small-molecule adenosine A3 receptor agonist in oncology and liver-disease clinical development. It is being evaluated in advanced hepatocellular carcinoma, MASH, and pancreatic cancer studies, including a pivotal phase III liver cancer program. The compound remains investigational.

Drug Class: Selective adenosine A3 receptor (A3AR) agonist
Approval Status: Investigational candidate in Phase III/II development; no approved marketing status stated.
Mechanism of Action: Selectively activates cell-surface A3AR and deregulates downstream Wnt and NF-kB signaling, which may induce apoptosis in A3AR-expressing tumor cells.

Indications

\Advanced hepatocellular carcinoma (Phase III investigational)\
\Metabolic dysfunction-associated steatohepatitis/MASH (Phase IIb investigational)\
\Pancreatic cancer (Phase IIa investigational)\

Related News

Cancer Pipeline Reports Show 45+ CSCC, 70+ Liver Cancer, and Multiple HCC Therapies in Development

Mar 20, 2026

DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.

Can-Fite's Namodenoson Shows Promise in Pancreatic Cancer and Obesity Studies

Mar 04, 2026

Can-Fite BioPharma's drug candidate namodenoson met its primary endpoint in a Phase 2a pancreatic cancer trial and demonstrated anti-obesity effects in a peer-reviewed preclinical study published in the International Journal of Obesity.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT05201404	Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis	RECRUITING	PHASE3
NCT04697810	Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)	RECRUITING	PHASE2